Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

    Limited submission

    Supporting biologic-based drug discovery and development for nervous system disorders through preclinical research, Phase I trials, and collaboration with NIH consultants and CROs.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

    This NIH program supports researchers in developing small-molecule neurotherapeutics by providing funding, expert guidance, and industry resources to advance drug candidates toward clinical testing.

    HHS-NIH11Forecasted Jun 16, 2027Forecasted

    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

    NIH supports development, testing, and clinical feasibility studies of therapeutic and diagnostic devices for nervous or neuromuscular disorders through milestone-driven cooperative agreements.

    HHS-NIH11Due Jan 28, 2027

    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)

    NIH supports national biomedical imaging and bioengineering centers that develop research-driven technologies, share them with investigators, and train researchers in their use.

    HHS-NIH11Forecasted Jan 25, 2027Forecasted

    Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

    This limited competition funds continued operation of National Cancer Institute biospecimen banks supporting national, early-phase, and experimental cancer clinical trials and translational research.

    HHS-NIH11Due Feb 11, 2027$18,000,000

    Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

    NCI funds collaborative teams to develop therapies for adult glioblastoma that cross the blood-brain barrier, advancing novel or repurposed agents from preclinical studies into Phase 0/1 trials.

    HHS-NIH11Due Jan 11, 2027$3,500,000Limited submission